6,9-二甲基-9H-嘌呤 | 14675-46-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 6,9-二甲基-9H-嘌呤
• 英文名称: 6,9-Dimethylpurin
• 英文别名: 6,9-Dimethyl-9H-purine；6,9-dimethylpurine
• CAS: 14675-46-8
• 化学式: C₇H₈N₄
• 分子量: 148.167
• InChiKey: VOPWYDLUZFPJNL-UHFFFAOYSA-N

物化性质

• 沸点：
  298.2±32.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6,9-二甲基-9H-嘌呤 、 双氧水 以32%的产率得到
  参考文献：
  名称：

  LAM F. L.; PARHAM J. C., J. AMER. CHEM. SOC. , 1975, 97, NO 10, 2839-2844

  摘要：

  DOI：
• 作为产物：
  描述：

  6-甲基嘌呤 、 硫酸二甲酯 以50%的产率得到
  参考文献：
  名称：

  BARAK, A.;AGRANAT, I., NOUV. J. CHIM., 1981, 5, N 10, 491-494

  摘要：

  DOI：

文献信息

• CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF
  申请人：SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD.

  公开号：US20210340169A1

  公开（公告）日：2021-11-04

  Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compound acting as a STING agonist.

  提供的是化合物（I）的化学式，其光学异构体，其药用盐，以及作为STING激动剂的该化合物的用途。
• Isothiazolyloxyphenylamidines and their use as fungicides
  申请人：KUNZ Klaus

  公开号：US20110130282A1

  公开（公告）日：2011-06-02

  The present invention relates to isothiazolyloxyphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms, and also to a composition for this purpose which comprises the isothiazolyloxyphenylamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or in their habitat.

  本发明涉及通式（I）的异噻唑氧基苯基胺类化合物，其制备方法，根据本发明用于控制不良微生物的胺类化合物的使用，以及包含根据本发明的异噻唑氧基苯基胺类化合物的用途的组合物。此外，本发明还涉及通过将根据本发明的化合物应用于微生物和/或其栖息地来控制不良微生物的方法。
• PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
  申请人：Ren Pingda

  公开号：US20120184568A1

  公开（公告）日：2012-07-19

  Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.

  本文描述了调节激酶活性的化合物的多态形式，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的治疗方法，包括PI3激酶活性。本文还提供了制备化合物、其多态形式和药物组合物的方法。
• Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
  申请人：Standring David

  公开号：US20080182814A1

  公开（公告）日：2008-07-31

  It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

  已经发现β-L-2'-去氧核苷能够对具有突变的耐药性乙型肝炎病毒起作用。提供了一种治疗宿主中拉米夫定耐药性HBV（M552V）的方法，包括给予β-L-2'-去氧核苷或其药学上可接受的盐、酯或前药。此外，还提供了一种预防拉米夫定耐药性HBV（M552V）突变发生在未接触过该病毒的宿主体内的方法，包括给予β-L-2'-去氧核苷或其药学上可接受的盐、酯或前药。还提供了一种预防和/或抑制宿主体内HBV双突变体（L528M/M552V）出现的方法，包括给予β-L-2'-去氧核苷或其药学上可接受的盐、酯或前药。
• Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
  申请人：Breslow Ronald

  公开号：US20070010536A1

  公开（公告）日：2007-01-11

  The present invention provides the compound having the formula: wherein each of R 1 and R 2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH 2 —; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.

  本发明提供了具有以下式子的化合物：其中R1和R2分别为取代或未取代的芳基、环烷基、环烷基氨基、萘基、吡啶氨基、哌啶基、叔丁基、芳氧基、芳基烷氧基或吡啶基；其中A为酰胺基、-O-、-S-、-NH-或-CH2-；n为3到8的整数。本发明还提供了一种选择性诱导肿瘤细胞生长停滞、终末分化和/或凋亡的方法，从而抑制这些细胞的增殖。此外，本发明还提供了一种治疗具有肿瘤细胞增殖特征的患者的方法。最后，本发明提供了一种包括药学上可接受的载体和上述化合物的治疗上可接受的剂量的药物组合物。